

John H Sampson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2444550/publications.pdf>

Version: 2024-02-01

354
papers

27,954
citations

4658

85
h-index

6836

155
g-index

359
all docs

359
docs citations

359
times ranked

20353
citing authors

#	ARTICLE	IF	CITATIONS
1	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	7.0	18
2	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	7.0	67
3	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac025.	0.7	18
4	Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype. <i>Methods in Molecular Biology</i> , 2022, 2410, 609-626.	0.9	2
5	A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2022, 40, e14015-e14015.	1.6	5
6	Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2005-2005.	1.6	5
7	A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2076-TPS2076.	1.6	0
8	Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. <i>Journal of Neuro-Oncology</i> , 2021, 151, 55-62.	2.9	42
9	A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. <i>Npj Vaccines</i> , 2021, 6, 12.	6.0	8
10	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
11	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 352.	12.8	77
12	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 3916-3925.	7.0	24
13	Targeting Immunometabolism in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 696402.	2.8	19
14	CLRM-09. INCORPORATING EXTERNAL CONTROL ARM IN MDNA55 RECURRENT GLIOBLASTOMA REGISTRATION TRIAL. <i>Neuro-Oncology Advances</i> , 2021, 3, iv3-iv3.	0.7	1
15	Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study. <i>Advances in Radiation Oncology</i> , 2021, 6, 100760.	1.2	11
16	Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. <i>Cancers</i> , 2021, 13, 5367.	3.7	10
17	For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. , 2021, 9, e003679.		11
18	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020, 20, 12-25.	28.4	389

#	ARTICLE	IF	CITATIONS
19	Determinants of Intraparenchymal Infusion Distributions: Modeling and Analyses of Human Glioblastoma Trials. <i>Pharmaceutics</i> , 2020, 12, 895.	4.5	10
20	GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody. <i>PLoS ONE</i> , 2020, 15, e0236374.	2.5	4
21	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5297-5303.	7.0	67
22	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1147-1158.	3.1	8
23	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	7.1	805
24	Comparative study of α -helical and β -sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. <i>Biomaterials Science</i> , 2020, 8, 3522-3535.	5.4	35
25	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. <i>Clinical Cancer Research</i> , 2020, 26, 5287-5296.	7.0	88
26	Oncolytic virus-derived type I interferon restricts CAR T cell therapy. <i>Nature Communications</i> , 2020, 11, 3187.	12.8	61
27	CAR T cells and checkpoint inhibition for the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 579-591.	3.1	37
28	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1586-1594.	7.0	103
29	Current multidisciplinary management of brain metastases. <i>Cancer</i> , 2020, 126, 1390-1406.	4.1	70
30	First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. , 2020, 8, e000213.		21
31	Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. <i>Journal of Clinical Investigation</i> , 2020, 130, 774-788.	8.2	47
32	MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2513-2513.	1.6	7
33	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2566-2566.	1.6	4
34	Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach. <i>Journal of Proteome Research</i> , 2019, 18, 3032-3041.	3.7	14
35	The current state of immunotherapy for gliomas: an eye toward the future. <i>Journal of Neurosurgery</i> , 2019, 131, 657-666.	1.6	79
36	The Evolving Modern Management of Brain Metastasis. <i>Clinical Cancer Research</i> , 2019, 25, 6570-6580.	7.0	83

#	ARTICLE	IF	CITATIONS
37	Reply to "Assembling the brain trust: the multidisciplinary imperative in neuro-oncology". Nature Reviews Clinical Oncology, 2019, 16, 522-523.	27.6	0
38	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. Cancer Research, 2019, 79, 3383-3394.	0.9	30
39	A Review of Anesthesia Simulation in Low-Income Countries. Current Anesthesiology Reports, 2019, 9, 1-9.	2.0	18
40	Challenges to curing primary brain tumours. Nature Reviews Clinical Oncology, 2019, 16, 509-520.	27.6	540
41	Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clinical Cancer Research, 2019, 25, 4202-4210.	7.0	207
42	ATIM-30. COMBATING RECURRENT GLIOBLASTOMA WITH MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, THROUGH MRI-GUIDED CONVECTIVE DELIVERY. Neuro-Oncology, 2019, 21, vi8-vi8.	1.2	1
43	PDCT-10. FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2019, 21, vi185-vi185.	1.2	0
44	ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2019, 21, vi6-vi6.	1.2	1
45	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. Neuro-Oncology, 2019, 21, vi7-vi7.	1.2	5
46	ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS. Neuro-Oncology, 2019, 21, vi8-vi8.	1.2	0
47	EXTH-09. FIRST-IN-HUMAN DOSING CONSIDERATIONS OF A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi84-vi84.	1.2	0
48	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. Neuro-Oncology, 2019, 21, vi12-vi12.	1.2	3
49	Effective effectors: How T cells access and infiltrate the central nervous system. , 2019, 197, 52-60.		11
50	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clinical Cancer Research, 2019, 25, 2042-2048.	7.0	77
51	Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. Clinical Cancer Research, 2019, 25, 358-368.	7.0	51
52	MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.. Journal of Clinical Oncology, 2019, 37, 2039-2039.	1.6	4
53	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. Journal of Clinical Oncology, 2019, 37, 2060-2060.	1.6	2
54	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. Journal of Clinical Oncology, 2019, 37, e13526-e13526.	1.6	8

#	ARTICLE	IF	CITATIONS
55	The effect of adoptive transfer of ex vivo activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.. Journal of Clinical Oncology, 2019, 37, 30-30.	1.6	1
56	Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology, 2018, 7, e1434464.	4.6	69
57	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology, 2018, 20, 674-686.	1.2	364
58	Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients: Are We Improving?. Neurosurgery, 2018, 83, 1269-1276.	1.1	13
59	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clinical Cancer Research, 2018, 24, 3611-3631.	7.0	39
60	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Research, 2018, 78, 256-264.	0.9	82
61	ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi1-vi2.	1.2	1
62	DDIS-02. NOVEL BISPECIFIC ACTIVATOR OF MACROPHAGES FOR THE TREATMENT OF GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi69-vi69.	1.2	0
63	ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2018, 20, vi9-vi9.	1.2	2
64	ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. Neuro-Oncology, 2018, 20, vi7-vi7.	1.2	0
65	RBTT-02. ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL. Neuro-Oncology, 2018, 20, vi234-vi234.	1.2	0
66	CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. Oncoimmunology, 2018, 7, e1502904.	4.6	11
67	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. Neuro-Oncology, 2018, 20, i93-i93.	1.2	2
68	A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis. Journal of Immunological Methods, 2018, 459, 90-93.	1.4	4
69	Recurrent Glioblastoma Treated with Recombinant Poliovirus. New England Journal of Medicine, 2018, 379, 150-161.	27.0	570
70	Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors. , 2018, , 693-705.		0
71	Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. Journal of Clinical Neuroscience, 2018, 56, 163-168.	1.5	31
72	Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine, 2018, 24, 1459-1468.	30.7	437

#	ARTICLE	IF	CITATIONS
73	Introduction. Update on adult neuro-oncology. <i>Neurosurgical Focus</i> , 2018, 44, E1.	2.3	0
74	Immunotherapy for High-Grade Gliomas. , 2017, , 177-192.		0
75	Prospect of rindopepimut in the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 507-513.	3.1	40
76	The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. <i>Journal of Neuro-Oncology</i> , 2017, 132, 83-87.	2.9	1
77	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. <i>Clinical Cancer Research</i> , 2017, 23, 1898-1909.	7.0	215
78	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	10.1	125
79	Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. <i>Neuro-Oncology</i> , 2017, 19, 1391-1397.	1.2	28
80	Immunomodulation for glioblastoma. <i>Current Opinion in Neurology</i> , 2017, 30, 361-369.	3.6	21
81	The Safety of available immunotherapy for the treatment of glioblastoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 277-287.	2.4	19
82	Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1049-1060.	3.0	84
83	Single fraction stereotactic radiosurgery for multiple brain metastases. <i>Advances in Radiation Oncology</i> , 2017, 2, 555-563.	1.2	44
84	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
85	A Supramolecular Vaccine Platform Based on α -Helical Peptide Nanofibers. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 3128-3132.	5.2	74
86	Accuracy of Novel Computed Tomographyâ€“Guided Frameless Stereotactic Drilling and Catheter System in Human Cadavers. <i>World Neurosurgery</i> , 2017, 106, 757-763.	1.3	5
87	Obituary. Robert H. Wilkins, MD, 1934â€“2017. <i>Journal of Neurosurgery</i> , 2017, 127, 1457-1458.	1.6	1
88	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited â€“ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e709-e710.	10.7	5
89	Advances and challenges: dendritic cell vaccination strategies for glioblastoma. <i>Expert Review of Vaccines</i> , 2017, 16, 27-36.	4.4	33
90	Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. <i>Oncolmmunology</i> , 2017, 6, e1256527.	4.6	59

#	ARTICLE	IF	CITATIONS
91	Immunotherapy for Brain Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2450-2456.	1.6	112
92	Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13532-e13532.	1.6	2
93	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2017, 35, e13533-e13533.	1.6	0
94	ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143. <i>Neuro-Oncology</i> , 2016, 18, vi21-vi21.	1.2	6
95	IMST-38. CAR T CELLS INDUCE COMPLETE REGRESSION OF MURINE GLIOBLASTOMA AFTER PRECONDITIONING HOSTS WITH TEMOZOLOMIDE. <i>Neuro-Oncology</i> , 2016, 18, vi94-vi95.	1.2	0
96	IMST-44. LYMPHOPENIA ENHANCES THE EFFICACY OF CAR T CELLS DELIVERED LOCO-REGIONALLY IN THE BRAIN FOR THE TREATMENT OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi96-vi96.	1.2	0
97	Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors. <i>Cancer Research</i> , 2016, 76, 5143-5150.	0.9	28
98	ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi17-vi18.	1.2	43
99	Emerging immunotherapies for glioblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 133-145.	2.4	34
100	Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. <i>Methods in Molecular Biology</i> , 2016, 1403, 819-838.	0.9	5
101	Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. <i>Clinical Cancer Research</i> , 2016, 22, 5164-5166.	7.0	13
102	Delivering therapy to target: improving the odds for successful drug development. <i>Therapeutic Delivery</i> , 2016, 7, 457-481.	2.2	24
103	Advances in Immunotherapy. <i>Neurosurgery</i> , 2016, 63, 85-87.	1.1	1
104	Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 205-211.	4.2	6
105	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 582-595.	7.0	88
106	Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2014-2014.	1.6	24
107	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2061-2061.	1.6	17
108	Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, e13518-e13518.	1.6	6

#	ARTICLE	IF	CITATIONS
109	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2079-TPS2079.	1.6	41
110	IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143. <i>Neuro-Oncology</i> , 2015, 17, v107.3-v107.	1.2	6
111	IMCT-19COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). <i>Neuro-Oncology</i> , 2015, 17, v111.4-v112.	1.2	0
112	107â€fReACT. <i>Neurosurgery</i> , 2015, 62, 198-199.	1.1	16
113	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. <i>OncImmunology</i> , 2015, 4, e994374.	4.6	41
114	Immunotherapy for malignant glioma. , 2015, 6, 68.		36
115	IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v109.1-v109.	1.2	20
116	Alternating Electric Fields for the Treatment of Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2511.	7.4	21
117	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro-Oncology</i> , 2015, 17, 854-861.	1.2	335
118	Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 419-427.	4.2	152
119	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	27.8	429
120	Editorial: Turning fluorescence into black and white. <i>Journal of Neurosurgery</i> , 2015, 122, 1356-1359.	1.6	4
121	Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care. <i>Journal of Visualized Experiments</i> , 2015, , .	0.3	17
122	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	10.7	582
123	Vaccination strategies for neuro-oncology: Table 1.. <i>Neuro-Oncology</i> , 2015, 17, vii15-vii25.	1.2	25
124	Editorial: Not everything that matters can be measured and not everything that can be measured matters. <i>Journal of Neurosurgery</i> , 2015, 123, 543-546.	1.6	3
125	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	10.1	307
126	Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: TableÂ1.. <i>Neuro-Oncology</i> , 2015, 17, 1043-1045.	1.2	24

#	ARTICLE	IF	CITATIONS
127	Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. <i>Journal of Neurochemistry</i> , 2015, 133, 730-738.	3.9	11
128	Editorial: Patient validation of retrospective data. <i>Journal of Neurosurgery</i> , 2015, 123, 969-971.	1.6	2
129	Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 65-74.	2.9	22
130	Are BiTEs the missing link in cancer therapy?. <i>Oncolmmunology</i> , 2015, 4, e1008339.	4.6	59
131	miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment. <i>Oncolmmunology</i> , 2015, 4, e990803.	4.6	11
132	Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide. <i>Cancer Immunology Research</i> , 2015, 3, 320-325.	3.4	20
133	Peptide vaccines for the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 123, 433-440.	2.9	41
134	Defining the Optimal Planning Target Volume in Image-Guided Stereotactic Radiosurgery of Brain Metastases: Results of a Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 100-108.	0.8	135
135	Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 79-94.	3.1	20
136	ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2009-2009.	1.6	56
137	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. <i>Journal of Clinical Oncology</i> , 2015, 33, 2068-2068.	1.6	9
138	Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. <i>Journal of Clinical Oncology</i> , 2015, 33, 3010-3010.	1.6	52
139	Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM). <i>Journal of Clinical Oncology</i> , 2015, 33, e13030-e13030.	1.6	0
140	EGFRVIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. <i>PLoS ONE</i> , 2014, 9, e94281.	2.5	99
141	Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e944054.	4.6	19
142	Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. <i>Oncolmmunology</i> , 2014, 3, e944059.	4.6	8
143	Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2047-2061.	1.8	19
144	Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions. <i>Journal of Neurosurgery</i> , 2014, 121, 262-276.	1.6	52

#	ARTICLE	IF	CITATIONS
145	Immunological targeting of cytomegalovirus for glioblastoma therapy. <i>Oncolmmunology</i> , 2014, 3, e29289.	4.6	23
146	Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. <i>Immunotherapy</i> , 2014, 6, 679-690.	2.0	88
147	Editorial on "Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial". <i>Neuro-Oncology</i> , 2014, 16, 169-170.	1.2	2
148	Impact of PhD training on scholarship in a neurosurgical career. <i>Journal of Neurosurgery</i> , 2014, 120, 730-735.	1.6	29
149	Editorial: SEER insights. <i>Journal of Neurosurgery</i> , 2014, 120, 297-299.	1.6	14
150	Editorial: Methodology and reporting of meta-analyses in the neurosurgical literature. <i>Journal of Neurosurgery</i> , 2014, 120, 791-795.	1.6	18
151	Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 2684-2694.	7.0	74
152	EGFRVIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. <i>Clinical Cancer Research</i> , 2014, 20, 972-984.	7.0	254
153	Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege. <i>Clinical Cancer Research</i> , 2014, 20, 5620-5629.	7.0	91
154	Epidermal growth factor receptor and variant III targeted immunotherapy. <i>Neuro-Oncology</i> , 2014, 16, viii20-viii25.	1.2	29
155	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1441-1458.	1.2	164
156	Antibody-Based Immunotherapy for Malignant Glioma. <i>Seminars in Oncology</i> , 2014, 41, 496-510.	2.2	11
157	A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. <i>Journal of Neurosurgery</i> , 2014, 121, 536-542.	1.6	28
158	Oncolytic polio virotherapy of cancer. <i>Cancer</i> , 2014, 120, 3277-3286.	4.1	67
159	Recurrent Malignant Gliomas. <i>Seminars in Radiation Oncology</i> , 2014, 24, 289-298.	2.2	40
160	Intracerebral delivery of a third generation EGFRVIII-specific chimeric antigen receptor is efficacious against human glioma. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 189-190.	1.5	94
161	Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. <i>Journal of Clinical Investigation</i> , 2014, 124, 5352-5367.	8.2	102
162	Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. <i>Journal of Radiosurgery and SBRT</i> , 2014, 3, 37-42.	0.2	3

#	ARTICLE	IF	CITATIONS
163	An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 375-386.	3.1	20
164	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. <i>Future Oncology</i> , 2013, 9, 977-990.	2.4	21
165	BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 983-987.	4.2	13
166	Radiotherapy and Radiosurgery for Tumors of the Central Nervous System. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 445-461.	1.5	10
167	Enhanced Oncolytic Virotherapy Through Oxidative Stress Inhibition. <i>Molecular Therapy</i> , 2013, 21, 1981-1983.	8.2	0
168	A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1649-1662.	4.2	7
169	Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. <i>Cancer Immunology Research</i> , 2013, 1, 163-167.	3.4	61
170	Concurrent Stereotactic Radiosurgery and Bevacizumab in Recurrent Malignant Gliomas: A Prospective Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 873-879.	0.8	94
171	Clinicopathological characteristics and treatment of rhabdoid glioblastoma. <i>Journal of Neurosurgery</i> , 2013, 119, 412-419.	1.6	22
172	Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1445-1448.	1.5	1
173	Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood-brain barrier. <i>Cancer Treatment Reviews</i> , 2013, 39, 261-269.	7.7	73
174	Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. <i>Journal of Immunological Methods</i> , 2013, 395, 14-20.	1.4	5
175	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. <i>Expert Review of Vaccines</i> , 2013, 12, 597-615.	4.4	60
176	Isocitrate dehydrogenase 1: what it means to the neurosurgeon. <i>Journal of Neurosurgery</i> , 2013, 118, 1176-1180.	1.6	20
177	Editorial: Subarachnoid hemorrhage trials. <i>Journal of Neurosurgery</i> , 2013, 118, 1-2.	1.6	4
178	Thickness of Subcutaneous Fat as a Risk Factor for Infection in Cervical Spine Fusion Surgery. <i>Journal of Bone and Joint Surgery - Series A</i> , 2013, 95, 323-328.	3.0	95
179	A novel bispecific antibody recruits T cells to eradicate tumors in the immunologically privileged central nervous system. <i>Oncolmmunology</i> , 2013, 2, e23639.	4.6	16
180	Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. <i>Oncolmmunology</i> , 2013, 2, e26757.	4.6	30

#	ARTICLE	IF	CITATIONS
181	Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 270-275.	7.1	120
182	Contemporary Surgical Management of Vestibular Schwannomas. Operative Neurosurgery, 2013, 72, ons103-ons115.	0.8	47
183	Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. PLoS ONE, 2013, 8, e59082.	2.5	56
184	Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. Journal of Clinical Investigation, 2013, 123, 3135-3145.	8.2	55
185	Rindopepimut. Drugs of the Future, 2013, 38, 147.	0.1	19
186	Editorial: Resection and survival. Journal of Neurosurgery, 2012, 116, 1169-1171.	1.6	0
187	Editorial. Journal of Neurosurgery, 2012, 116, 336-340.	1.6	1
188	Editorial. Journal of Neurosurgery, 2012, 116, 346-348.	1.6	1
189	Editorial: Convection-enhanced delivery. Journal of Neurosurgery, 2012, 117, 1126-1127.	1.6	1
190	Editorial. Journal of Neurosurgery, 2012, 116, 280-282.	1.6	1
191	Toxin-Based Targeted Therapy for Malignant Brain Tumors. Clinical and Developmental Immunology, 2012, 2012, 1-15.	3.3	24
192	Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas. Neurosurgery, 2012, 70, 234-244.	1.1	204
193	Stereotactic Radiosurgery and Bevacizumab for Recurrent Glioblastoma Multiforme. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 695-699.	4.9	24
194	Regulatory T Cells Move in When Gliomas Say "No". Clinical Cancer Research, 2012, 18, 6086-6088.	7.0	11
195	Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2012, 82, 58-66.	0.8	74
196	Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in Patients With Recurrent Malignant Gliomas. International Journal of Radiation Oncology Biology Physics, 2012, 82, 2018-2024.	0.8	155
197	Enzyme redesign guided by cancer-derived IDH1 mutations. Nature Chemical Biology, 2012, 8, 887-889.	8.0	22
198	The limitations of imaging response criteria. Lancet Oncology, The, 2012, 13, 1064-1065.	10.7	2

#	ARTICLE	IF	CITATIONS
199	The Use of Motor Mapping to Aid Resection of Eloquent Gliomas. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 215-225.	1.7	8
200	A Pilot Study of IL-2R β Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e31046.	2.5	98
201	Phase I trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2012, 108, 499-506.	2.9	41
202	Phase II study of Gleevec $\text{\textcircled{R}}$ plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2012, 106, 409-415.	2.9	78
203	Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 155-164.	2.9	123
204	Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas. <i>Current Drug Discovery Technologies</i> , 2012, 9, 237-255.	1.2	4
205	Convection Enhanced Delivery of Macromolecules for Brain Tumors. <i>Current Drug Discovery Technologies</i> , 2012, 9, 305-310.	1.2	29
206	Bispecific antibodies engage T cells for antitumor immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 843-853.	3.1	78
207	Monitoring Radiographic Brain Tumor Progression. <i>Toxins</i> , 2011, 3, 191-200.	3.4	25
208	Imaging of Convection Enhanced Delivery of Toxins in Humans. <i>Toxins</i> , 2011, 3, 201-206.	3.4	20
209	A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors. <i>PLoS ONE</i> , 2011, 6, e16031.	2.5	48
210	Colocalization of Gadolinium-Diethylene Triamine Pentaacetic Acid With High-Molecular-Weight Molecules After Intracerebral Convection-Enhanced Delivery in Humans. <i>Neurosurgery</i> , 2011, 69, 668-676.	1.1	67
211	Monoclonal antibody blockade of IL-2 receptor β during lymphopenia selectively depletes regulatory T cells in mice and humans. <i>Blood</i> , 2011, 118, 3003-3012.	1.4	104
212	A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 414-427.	4.9	113
213	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 54-68.	4.4	79
214	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 57-66.	2.9	118
215	Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. <i>Journal of Neuro-Oncology</i> , 2011, 101, 267-277.	2.9	64
216	Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Journal of Neuro-Oncology</i> , 2011, 103, 371-379.	2.9	83

#	ARTICLE	IF	CITATIONS
217	Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Cancer</i> , 2011, 117, 5351-5358.	4.1	80
218	Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?. <i>Neuro-Oncology</i> , 2011, 13, 3-13.	1.2	97
219	Editorial. <i>Journal of Neurosurgery</i> , 2011, 115, 463-466.	1.6	11
220	Editorial: Low-grade glioma. <i>Journal of Neurosurgery</i> , 2011, 114, 563-565.	1.6	2
221	Editorial: Resection of vestibular schwannomas. <i>Journal of Neurosurgery</i> , 2011, 114, 1216-1217.	1.6	2
222	Editorial: Epidemiology. <i>Journal of Neurosurgery</i> , 2011, 115, 256-258.	1.6	1
223	Editorial. <i>Journal of Neurosurgery</i> , 2011, 115, 245-247.	1.6	4
224	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 324-333.	1.2	306
225	Bevacizumab-Induced Reversible Posterior Leukoencephalopathy Syndrome and Successful Retreatment in a Patient With Glioblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e739-e742.	1.6	26
226	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2011, 29, e519-e520.	1.6	1
227	The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 4119-4124.	7.0	133
228	Is Cytomegalovirus a Therapeutic Target in Glioblastoma?. <i>Clinical Cancer Research</i> , 2011, 17, 4619-4621.	7.0	27
229	Reply to M.S. Lesniak. <i>Journal of Clinical Oncology</i> , 2011, 29, 3105-3106.	1.6	9
230	A promising cancer vaccine. <i>Future Oncology</i> , 2011, 7, 331-334.	2.4	1
231	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011, 13, 353-361.	1.2	105
232	Malignant Glioma Immunotherapy: A Peptide Vaccine from Bench to Bedside. , 2011, , 349-356.		0
233	Immunotherapy Approaches for Malignant Glioma From 2007 to 2009. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 259-266.	4.2	41
234	Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. <i>Journal of Neuro-Oncology</i> , 2010, 98, 1-7.	2.9	46

#	ARTICLE	IF	CITATIONS
235	Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. <i>Journal of Neuro-Oncology</i> , 2010, 98, 427-430.	2.9	7
236	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 96, 219-230.	2.9	208
237	Stereotactic Radiosurgery in the Treatment of a Dural Carotid-Cavernous Fistula. <i>Journal of Neuro-Ophthalmology</i> , 2010, 30, 138-144.	0.8	7
238	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4722-4729.	1.6	702
239	Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 871-881.	1.2	407
240	Poor drug distribution as a possible explanation for the results of the PRECISE trial. <i>Journal of Neurosurgery</i> , 2010, 113, 301-309.	1.6	219
241	The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention. <i>Neurosurgery Clinics of North America</i> , 2010, 21, 125-137.	1.7	67
242	Clinical Applications of a Peptide-Based Vaccine for Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2010, 21, 95-109.	1.7	21
243	Convection-Enhanced Drug Delivery to the Brain. <i>NeuroMethods</i> , 2010, , 291-318.	0.3	3
244	Processing of natural resourced hydroxyapatite ceramics from fish scale. <i>Advances in Applied Ceramics</i> , 2010, 109, 234-239.	1.1	12
245	An epidermal growth factor receptor variant IIIâ€‘targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2773-2779.	4.1	262
246	Phase II Trial of Temozolomide Plus O ⁶ -Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1262-1267.	1.6	280
247	Phase II Trial of Gliadel plus O ⁶ -Benzylguanine in Adults with Recurrent Glioblastoma Multiforme. <i>Clinical Cancer Research</i> , 2009, 15, 1064-1068.	7.0	59
248	The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1087-1098.	3.1	79
249	Phase I trial of temozolomide plus O ⁶ -benzylguanine 5-day regimen with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2009, 11, 556-561.	1.2	39
250	IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era. <i>International Journal of Cancer</i> , 2009, 125, 680-687.	5.1	73
251	Phase 1 trial of temozolomide plus irinotecan plus O ⁶ -benzylguanine in adults with recurrent malignant glioma. <i>Cancer</i> , 2009, 115, 2964-2970.	4.1	28
252	Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors. <i>Neurotherapeutics</i> , 2009, 6, 527-538.	4.4	37

#	ARTICLE	IF	CITATIONS
253	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. <i>Journal of Neuro-Oncology</i> , 2009, 95, 393-400.	2.9	53
254	EGFRvIII-targeted Vaccination Therapy of Malignant Glioma. <i>Brain Pathology</i> , 2009, 19, 713-723.	4.1	118
255	A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. <i>Journal of Neurochemistry</i> , 2009, 109, 1079-1086.	3.9	85
256	Stereotactic Body Radiotherapy for Lesions of the Spine and Paraspinal Regions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1369-1375.	0.8	112
257	Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of ^{125}I -particle-emitting ^{211}At -labeled trastuzumab. <i>Nuclear Medicine and Biology</i> , 2009, 36, 659-669.	0.6	43
258	Proteomic and immunologic analyses of brain tumor exosomes. <i>FASEB Journal</i> , 2009, 23, 1541-1557.	0.5	369
259	Paraganglioma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 304-307.	1.3	57
260	Cryptococcal meningitis in patients with glioma: a report of two cases. <i>Journal of Neuro-Oncology</i> , 2008, 89, 51-53.	2.9	25
261	EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 115-121.	4.2	36
262	Molecular strategies for the treatment of malignant glioma—genes, viruses, and vaccines. <i>Neurosurgical Review</i> , 2008, 31, 141-155.	2.4	39
263	Immunotherapy of malignant brain tumors. <i>Immunological Reviews</i> , 2008, 222, 70-100.	6.0	87
264	Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. <i>Journal of Immunological Methods</i> , 2008, 339, 74-81.	1.4	48
265	Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. <i>Seminars in Immunology</i> , 2008, 20, 267-275.	5.6	156
266	Selective Modification of Antigen-Specific T Cells by RNA Electroporation. <i>Human Gene Therapy</i> , 2008, 19, 511-521.	2.7	39
267	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. <i>Neuro-Oncology</i> , 2008, 10, 320-329.	1.2	179
268	Combating immunosuppression in glioma. <i>Future Oncology</i> , 2008, 4, 433-442.	2.4	65
269	Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 717-732.	2.4	13
270	Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. <i>Neuro-Oncology</i> , 2008, 10, 98-103.	1.2	109

#	ARTICLE	IF	CITATIONS
271	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. <i>Clinical Cancer Research</i> , 2008, 14, 7068-7073.	7.0	166
272	Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. <i>Neuro-Oncology</i> , 2008, 10, 10-18.	1.2	323
273	A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells. <i>Clinical Cancer Research</i> , 2008, 14, 5759-5768.	7.0	111
274	Cholesterol granuloma of the lateral ventricle. <i>Journal of Neurosurgery</i> , 2008, 108, 357-360.	1.6	6
275	Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. <i>Journal of Neurosurgery</i> , 2008, 109, 874-880.	1.6	91
276	Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2007, 25, 4722-4729.	1.6	1,285
277	Induction of Hyperintense Signal on T2-Weighted MR Images Correlates with Infusion Distribution from Intracerebral Convection-Enhanced Delivery of a Tumor-Targeted Cytotoxin. <i>American Journal of Roentgenology</i> , 2007, 188, 703-709.	2.2	67
278	Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. <i>Neuro-Oncology</i> , 2007, 9, 343-353.	1.2	112
279	Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 837-844.	1.6	313
280	Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function. <i>Clinical Cancer Research</i> , 2007, 13, 2158-2167.	7.0	293
281	INTRACEREBRAL INFUSATE DISTRIBUTION BY CONVECTION-ENHANCED DELIVERY IN HUMANS WITH MALIGNANT GLIOMAS. <i>Operative Neurosurgery</i> , 2007, 60, 89-99.	0.8	95
282	CONVECTION-ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN-13-PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS. <i>Neurosurgery</i> , 2007, 61, 1031-1038.	1.1	126
283	Viruses in the treatment of malignant glioma. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 321-324.	2.8	10
284	Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. <i>Journal of Neuroimmunology</i> , 2007, 182, 63-72.	2.3	7
285	Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2007, 83, 53-60.	2.9	92
286	Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.. <i>Clinical Cancer Research</i> , 2006, 12, 1349-1354.	7.0	55
287	Preoperative Functional MR Imaging Localization of Language and Motor Areas: Effect on Therapeutic Decision Making in Patients with Potentially Resectable Brain Tumors. <i>Radiology</i> , 2006, 240, 793-802.	7.3	193
288	Treatment of Neoplastic Meningitis With Intrathecal 9-Nitro-camptothecin. <i>Neurologia Medico-Chirurgica</i> , 2006, 46, 485-490.	2.2	6

#	ARTICLE	IF	CITATIONS
289	Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in Murine Glioma without Eliminating Regulatory T Cells. <i>Clinical Cancer Research</i> , 2006, 12, 4294-4305.	7.0	152
290	Convection-enhanced delivery of therapeutics for brain disease, and its optimization. <i>Neurosurgical Focus</i> , 2006, 20, E12.	2.3	204
291	Phase I Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2006, 12, 860-868.	7.0	187
292	Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T Cells in Patients with Malignant Glioma Reveals Differential Expression of the Immunologic Transcriptome Compared with T Cells from Healthy Volunteers. <i>Clinical Cancer Research</i> , 2006, 12, 7306-7315.	7.0	65
293	Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. <i>Neurosurgical Focus</i> , 2006, 20, E14.	2.3	54
294	Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant Glioma. <i>Cancer Research</i> , 2006, 66, 3294-3302.	0.9	533
295	Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. <i>Neurosurgical Focus</i> , 2006, 20, E15.	2.3	68
296	Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with ¹³¹ I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. <i>Journal of Nuclear Medicine</i> , 2006, 47, 912-8.	5.0	32
297	Contacting Neurosurgery. <i>Neurosurgery</i> , 2005, 56, 559.	1.1	232
298	Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study. <i>Neuro-Oncology</i> , 2005, 7, 90-96.	1.2	54
299	Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2005, 23, 7178-7187.	1.6	220
300	Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2005, 23, 9359-9368.	1.6	313
301	Brain Metastases from Malignant Melanoma. , 2005, , 430-438.		2
302	Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme. <i>Clinical Cancer Research</i> , 2004, 10, 3216-3224.	7.0	151
303	Phase II Trial of Gefitinib in Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 133-142.	1.6	677
304	Phase I trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. <i>Neuro-Oncology</i> , 2004, 6, 145-153.	1.2	24
305	Poliovirus receptor CD155-targeted oncolysis of glioma. <i>Neuro-Oncology</i> , 2004, 6, 208-217.	1.2	116
306	Treatment of Intracerebral Neoplasia and Neoplastic Meningitis with Regional Delivery of Oncolytic Recombinant Poliovirus. <i>Clinical Cancer Research</i> , 2004, 10, 4831-4838.	7.0	49

#	ARTICLE	IF	CITATIONS
307	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. <i>Neuro-Oncology</i> , 2004, 6, 134-144.	1.2	42
308	How does the immune system attack cancer?. <i>Current Problems in Surgery</i> , 2004, 41, 15-132.	1.1	14
309	Microvascular Decompression for Glossopharyngeal Neuralgia: Long-term Effectiveness and Complication Avoidance. <i>Neurosurgery</i> , 2004, 54, 884-890.	1.1	122
310	Novel Therapeutic Approaches for High-Grade Gliomas. <i>Frontiers in Neuroscience</i> , 2004, , 155-180.	0.0	0
311	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 161-176.	2.9	6
312	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2003, 65, 27-35.	2.9	222
313	The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. <i>Journal of Neuro-Oncology</i> , 2003, 64, 161-176.	2.9	33
314	Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2003, 21, 646-651.	1.6	246
315	Adoptive Immunotherapy for Malignant Glioma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 157-166.	2.0	21
316	Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. <i>Clinical Cancer Research</i> , 2003, 9, 4247-54.	7.0	175
317	Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5514-20.	7.0	63
318	Phase II Trial of Carmustine Plus O6-Benzylguanaine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2277-2283.	1.6	178
319	Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma. <i>Neurosurgery</i> , 2002, 50, 158-166.	1.1	81
320	Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma. <i>Neurosurgery</i> , 2002, 50, 158-166.	1.1	66
321	Clinical immunotherapy for brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002, 12, 641-664.	1.0	11
322	Viruses in the treatment of brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002, 12, 553-570.	1.0	11
323	Phase II Trial of Murine ¹³¹ I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas. <i>Journal of Clinical Oncology</i> , 2002, 20, 1389-1397.	1.6	227
324	Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. <i>Cancer Immunology, Immunotherapy</i> , 2002, 50, 639-652.	4.2	20

#	ARTICLE	IF	CITATIONS
325	Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. <i>Cancer Research</i> , 2002, 62, 3335-9.	0.9	210
326	Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). <i>Clinical Cancer Research</i> , 2002, 8, 3496-502.	7.0	138
327	Phase I study of Gliadel [®] wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. <i>Neuro-Oncology</i> , 2001, 3, 246-250.	1.2	47
328	Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. <i>Journal of Neuroimmunology</i> , 2000, 103, 16-25.	2.3	128
329	Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2000, 18, 3522-3528.	1.6	125
330	Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 7503-7508.	7.1	177
331	EGFRvIII: an oncogene deletion mutant cell surface receptor target expressed by multiple tumour types. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 497-514.	1.0	5
332	Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. <i>Journal of Neuro-Oncology</i> , 1999, 44, 233-241.	2.9	18
333	Monoclonal antibody therapy of human gliomas: current status and future approaches. <i>Cancer and Metastasis Reviews</i> , 1999, 18, 451-464.	5.9	51
334	Local production of TGF β 1 inhibits cerebral edema, enhances TNF- α induced apoptosis and improves survival in a murine glioma model. <i>Journal of Neuroimmunology</i> , 1998, 86, 46-52.	2.3	28
335	Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. <i>Journal of Neurosurgery</i> , 1998, 88, 11-20.	1.6	483
336	Cytokine-Based Gene Therapy for Brain Tumors. , 1998, , 231-294.		1
337	Characterization of a Spontaneous Murine Astrocytoma and Abrogation of Its Tumorigenicity by Cytokine Secretion. <i>Neurosurgery</i> , 1997, 41, 1365-1372.	1.1	88
338	A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. <i>Journal of Neuroimmunology</i> , 1997, 78, 34-46.	2.3	34
339	Recurrence of a cerebral arteriovenous malformation after surgical excision. <i>Journal of Neurosurgery</i> , 1996, 84, 879-882.	1.6	77
340	Metastatic Melanoma to the Spine Demographics, Risk Factors, and Prognosis in 114 Patients. <i>Spine</i> , 1995, 20, 2141-2146.	2.0	39
341	Dorsal root entry zone lesions for intractable pain after trauma to the conus medullaris and cauda equina. <i>Journal of Neurosurgery</i> , 1995, 82, 28-34.	1.6	44
342	The gravitational shunt: An alternative approach to cerebrospinal fluid shunting. <i>World Neurosurgery</i> , 1993, 40, 112-118.	1.3	1

#	ARTICLE	IF	CITATIONS
343	Facial pain due to vascular lesions of the brain stem relieved by dorsal root entry zone lesions in the nucleus caudalis. Journal of Neurosurgery, 1992, 77, 473-475.	1.6	16
344	Solitary Eosinophilic Granuloma Invading the Clivus of an Adult. Neurosurgery, 1992, 31, 755-757.	1.1	11
345	Solitary Eosinophilic Granuloma Invading the Clivus of an Adult. Neurosurgery, 1992, 31, 755-757.	1.1	18
346	Design and statistical analysis of clinical trials for glioma therapy. , 0 , 169-189.		0
347	Radiation therapy for gliomas. , 0 , 49-75.		0
348	Immunotherapy for gliomas. , 0 , 91-120.		0
349	Neuropathology of gliomas. , 0 , 146-168.		0
350	Health-related quality of life in glioma patients. , 0 , 190-204.		0
351	Chemotherapy for gliomas. , 0 , 76-90.		0
352	Glioma surgery. , 0 , 24-48.		0
353	Neuroradiology of gliomas. , 0 , 121-145.		0
354	Genetics of glioma. , 0 , 1-23.		1